24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)

May 22, 2025

DENVER, Colo., 22 May, 2025 (www.247marketnews.com) – (NASDAQ:POAI) are discussed in this article.
Predictive Oncology Inc. is currently experiencing a downward trend, with its shares trading at $1.007 in the pre-market session, reflecting a 7.61% decrease from the previous close of $1.090. The trading volume reached 2.06 million shares, indicating heightened investor interest, potentially influenced by prevailing market sentiments. A continued decline below critical support levels may suggest further drops, while resistance has been established around $1.09. Market participants are advised to monitor volume trends closely, as they may reveal potential oversold conditions that could lead to reversal opportunities.

In addition to the fluctuations in stock performance, Predictive Oncology is making significant strides in the field of AI-driven drug discovery. The company is leveraging an extensive biobank comprising over 150,000 live cell tumor samples to push boundaries in innovative drug discovery, biomarker identification, and drug repurposing, utilizing advanced artificial intelligence and machine learning methodologies. Recent developments in the industry, such as Regeneron Pharmaceuticals’ acquisition of 23andMe, further underscore the vital role that data plays within the biopharmaceutical sector.

Raymond Vennare, Chairman and CEO of Predictive Oncology, highlighted the company’s recent milestone in AI-enabled cancer drug discovery, having developed predictive tumor response models for 21 untested compounds targeting prevalent cancer types, including breast, colon, and ovarian cancers. These models were created without prior response data, emphasizing the transformative capabilities of AI in early-stage drug discovery.

Predictive Oncology’s proprietary platform facilitates swift drug response modeling, allowing partners to significantly reduce research timelines and mitigate risks associated with drug development, optimizing their return on investment. As the life sciences landscape evolves, the integration of artificial intelligence, genomic data, and real-world insights positions Predictive Oncology as a key player in the advancement of precision medicine, enhancing drug discovery processes and improving patient outcomes on a global scale.

Related news for (POAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.